ZLB Behring Release: VIRTUE, Largest Clinical Trial Of Subcutaneous Immunoglobulin Therapy, Opens To Primary Immunodeficiency Patients Across The U.S.

KING OF PRUSSIA, Pa., Sept. 12 /PRNewswire/ -- ZLB Behring has announced the launch of the VIRTUE Trial, a Phase IV clinical trial of the study medication Vivaglobin® (Immune Globulin Subcutaneous, Human), the first and only U.S. Food and Drug Administration-approved subcutaneous immunoglobulin (Ig) treatment for patients with primary immunodeficiency (PI). VIRTUE [Vivaglobin Investigator Research Trial on Use and Experience], will evaluate patient satisfaction and annual rate of serious bacterial infection using Vivaglobin subcutaneous administration for one year after conversion from intravenous immunoglobulin therapy.